Craig H. Moskowitz

1997–2025 年に発表

102
論文数
18,972
被引用数
71
h 指数
99
i10 指数

被引用数

Craig H. Moskowitz の年別被引用数1997 年: 被引用 1 件1998 年: 被引用 4 件1999 年: 被引用 4 件2000 年: 被引用 5 件2001 年: 被引用 5 件2002 年: 被引用 4 件2003 年: 被引用 11 件2004 年: 被引用 14 件2005 年: 被引用 38 件2006 年: 被引用 54 件2007 年: 被引用 75 件2008 年: 被引用 50 件2009 年: 被引用 60 件2010 年: 被引用 73 件2011 年: 被引用 86 件2012 年: 被引用 84 件2013 年: 被引用 74 件2014 年: 被引用 91 件2015 年: 被引用 153 件2016 年: 被引用 136 件2017 年: 被引用 179 件2018 年: 被引用 207 件2019 年: 被引用 612 件2020 年: 被引用 736 件2021 年: 被引用 634 件2022 年: 被引用 461 件2023 年: 被引用 307 件2024 年: 被引用 482 件2025 年: 被引用 202 件2026 年: 被引用 1 件

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 1,653 件、この内訳の 28.9%中国: 引用元論文 383 件、この内訳の 6.7%ドイツ: 引用元論文 381 件、この内訳の 6.7%イタリア: 引用元論文 367 件、この内訳の 6.4%フランス: 引用元論文 334 件、この内訳の 5.9%イギリス: 引用元論文 328 件、この内訳の 5.7%カナダ: 引用元論文 234 件、この内訳の 4.1%スペイン: 引用元論文 187 件、この内訳の 3.3%スイス: 引用元論文 184 件、この内訳の 3.2%オーストラリア: 引用元論文 174 件、この内訳の 3%オランダ: 引用元論文 166 件、この内訳の 2.9%日本: 引用元論文 146 件、この内訳の 2.6%
0%28.9%その他 20.6%

分野

  • Medicine85.7%
  • Biochemistry, Genetics and Molecular Biology9.2%
  • Immunology and Microbiology2.5%
  • Psychology0.9%
  • Materials Science0.3%
  • Computer Science0.2%
  • その他1.2%

トピック

  • Lymphoma Diagnosis and Treatment19%
  • CAR-T cell therapy research9.8%
  • CNS Lymphoma Diagnosis and Treatment6.6%
  • Cancer Immunotherapy and Biomarkers4.9%
  • Chronic Lymphocytic Leukemia Research4.3%
  • Viral-associated cancers and disorders3.9%
  • その他51.5%

共著者

全論文

検索で開く
  1. Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era

    著者: , , , , , , , , , , , , , - Journal of Clinical Oncology 2010 被引用: 1,622

  2. Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma

    著者: , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2012 被引用: 1,520

  3. Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma

    著者: , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2017 被引用: 985

  4. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , , - The Lancet 2015 被引用: 734

  5. Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results

    著者: , , , , , , , , , , , , , , , , - Blood 2021 被引用: 218

  6. Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups

    著者: , , , , , , , , , , , , , , , , , , , , , , , , - Blood Cancer Journal 2020 被引用: 203

  7. Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , M. Lia Palomba, Ariela Noy, Matthew J. Matasar, Georgios Pongas, Gilles Salles, Santosha A. Vardhana, Beatriz Wills Sanín, Gottfried von Keudell, Joachim Yahalom, Ahmet Doǧan, Andrew D. Zelenetz, Craig H. Moskowitz - Journal of Clinical Oncology 2021 被引用: 199

  8. Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jon Glass, Scott Peak, Enrico C. Lallana, Vaios Hatzoglou, Anne S. Reiner, Philip H. Gutin, Jason T. Huse, Katherine S. Panageas, Thomas G. Graeber, Nikolaus Schultz, Lisa M. DeAngelis, Ingo K. Mellinghoff - Cancer Discovery 2017 被引用: 402

  9. Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphoma

    著者: , , , , , , , , , , , , , , , , , - Blood 2023 被引用: 105

  10. Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087

    著者: , , , , , , , , , , , , , , , , , - Blood 2019 被引用: 329

  11. Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study

    著者: , , , , , , , , , , , , , , , , , - Bone Marrow Transplantation 2015 被引用: 316

  12. Nivolumab+AVD in Advanced-Stage Classic Hodgkin’s Lymphoma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Kristie A. Blum, Anamarija M. Perry, Alexandra E. Kovach, David Hodgson, Louis S. Constine, Lale Kostakoglu Shields, Anca Prica, Hildy Dillon, Richard F. Little, Margaret A. Shipp, Michael Crump, Brad S. Kahl, John P. Leonard, Sonali M. Smith, Joo Y. Song, Kara M. Kelly, Jonathan W. Friedberg - New England Journal of Medicine 2024 被引用: 200

  13. R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma

    著者: , , , , , , , , , , , , , , - Blood 2015 被引用: 345

  14. The Impact of Semiautomatic Segmentation Methods on Metabolic Tumor Volume, Intensity, and Dissemination Radiomics in 18F-FDG PET Scans of Patients with Classical Hodgkin Lymphoma

    著者: , , , , , , , , , , , - Journal of Nuclear Medicine 2022 被引用: 58

  15. Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse

    著者: , , , , , , , , , , , , , , , - Blood 2018 被引用: 245

  16. Factors Associated With Unmet Supportive Care Needs and Emergency Department Visits and Hospitalizations in Ambulatory Oncology

    著者: , , , , , , , , , , - JAMA Network Open 2023 被引用: 46

  17. Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure

    著者: , , , , , , , , , , - Journal of Clinical Oncology 2016 被引用: 672

  18. Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma

    著者: , , , , , , , , , , , , , , , - Blood 2017 被引用: 320

  19. Molecular Evolution of Classic Hodgkin Lymphoma Revealed Through Whole-Genome Sequencing of Hodgkin and Reed Sternberg Cells

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Mikhail Roshal, Lisa Giulino‐Roth - Blood Cancer Discovery 2023 被引用: 62

  20. Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma

    著者: , , , , , , , , , - Blood 2017 被引用: 295

  21. PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study

    著者: , , , , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2015 被引用: 266

  22. Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: A report of 5 cases from the Southern Network on Adverse Reactions (SONAR) project

    著者: , , , , , , , , , , , , , , , , , - Cancer 2014 被引用: 136

  23. Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapse

    著者: , , , , , , , , , , , , , , , , - Blood Cancer Journal 2019 被引用: 122

  24. Brentuximab Vedotin Combined With Chemotherapy in Patients With Newly Diagnosed Early-Stage, Unfavorable-Risk Hodgkin Lymphoma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Joachim Yahalom, Craig H. Moskowitz - Journal of Clinical Oncology 2021 被引用: 57